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Abstract: Fructose bisphosphatase-1 (FBP1) is a rate limiting enzyme in 
gluconeogenesis that converts fructose-1,6-bisphosphate (F1,6BP) to fructose-6-
phosphate (F6P). It is active in liver, kidney and skeletal muscle cells. This study 
suggests that FBP1 plays a novel non-gluconeogenic role in T cells. Targeted 
metabolomics using [13C]-6-glucose revealed a labeling pattern of F6P in stimulated 
CD3+ T cells that could only have resulted from FBP1 enzymatic activity. Following 
stimulation, T cells expressed a 27kD form of FBP1, in addition to the full-length 37kD 
protein. The hypothesis that T cells utilize an alternative translational start site to express 
a shorter, constitutively active, form is being tested. Future studies will also test the 
hypothesis that FBP1 activity increases carbon flux into the pentose phosphate pathway 
(PPP), to facilitate increased production of reducing agent and co-factor, NADPH, in 
preparation for proliferation. This research could contribute significantly to our 
understanding of T cell physiology and cancer cell metabolism. 
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Chapter 1: Introduction 
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T lymphocyte metabolism as a model for cancer and proliferative metabolism 
T lymphocytes (T cells) have been used as models for studying proliferative and cancer 
cell metabolism (1). T cells mature in the thymus and are constantly in circulation in the 
blood and the lymphatic system in the naïve (unstimulated) state. They are activated via 
signaling pathways mediated by T cell receptors (TCRs) on these cells, upon 
encountering a cognate antigen. The foreign antigens are presented by antigen presenting 
cells (APCs) as a part of the major histocompatibility complex (MHC). Activated T cells 
then proliferate and differentiate into effector T cells acquiring abilities to produce 
substances like cytokines to combat the inflammation effectively (2). 
 
Quiescent and activated T cells are functionally and phenotypically quite different. The 
switch from a naïve cell to a proliferating cell is supported by changes in the cell’s 
metabolic framework. Quiescent T cells have a resting metabolic phenotype, catabolizing 
fuels to support cell survival (Fig. 1) (1). The consumed glucose is metabolized through 
glycolysis, the tricarboxylic acid (TCA) cycle and subsequent oxidative phosphorylation 
process (OXPHOS) to generate large amounts of ATP (3). There is stagnancy in growth 
and cell division, and the cells maintain a status quo unless encountered by an antigen. 
Fig. 1- Metabolic differences between quiescent and activated T cells 
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Activation of T cells, on the other hand results in rapid growth, proliferation and 
acquisition of effector functions (3). Sustaining the dramatic changes that take place in a 
T cell upon activation requires extensive metabolic reprogramming, and a switch to 
anabolic metabolism to help them grow and proliferate (4). The requirement of activated 
T cells for biosynthetic precursors is almost as significant as their need for ATP. 
Stimulated T lymphocytes become highly glycolytic and increase their rates of aerobic 
glycolysis to support their energetic and biosynthetic demands (4). Activated T cells thus 
utilize more glucose to divert it to biosynthetic intermediates, decreasing the amount of 
glucose entering the TCA cycle. Glycolysis as a means to generate ATP is energetically 
inefficient, but it branches into pathways like the pentose phosphate shunt that generate 
several important building blocks such as nucleotides and lipids for biomass 
production(1). 
The proliferative signals that drive metabolic reprogramming are common to T cells and 
cancer cells. Aerobic glycolysis is utilized in both systems for energy and biosynthesis 
(1). Like activated T cells, tumors enter a stage, albeit more gradually, of rapid 
proliferation and growth, with an increase in cellular metabolic activity (5). Hypoxic 
environments and increased nutrient requirements cause these cells to adopt a similar 
metabolic profile during activation and tumorigenesis, respectively (1, 6). T cells thus 
offer a useful platform to study metabolic reprogramming in the proliferating phenotype. 
Importance of the pentose phosphate pathway:  
Increased glycolysis, in turn, also increases the supply of fuel to the pentose phosphate 
pathway (PPP), which is a branch of glycolysis, diverting G6P to form pentose 
phosphates and NADPH (Fig. 2).  These pentose phosphate intermediates are of special 
importance in highly proliferative cells like activated T lymphocytes and tumor, which 
require them as precursors for nucleotide synthesis (4). NADPH is an important 
byproduct of this pathway, actively involved in neutralizing reactive oxygen species 
(ROS) in the cells (7). Activated T cells and tumors experience high levels of oxidative 
stress due to increased metabolic activity (4). The generation of NADPH via the PPP is 
critical in the defense against reactive oxygen species in the cells as it generates reduced 
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glutathione, a species that scavenges free radicals in the cell.  Moreover, NADPH is also 
involved in the production, from Acetyl-coA, of fatty acid, used in synthesis of cellular  
membranes (8). Thus, mechanisms that increase the production of NADPH through the 
PPP are critical in sustaining growth and increasing proliferation. 
 
Production of glucose from endogenous substrates to maintain blood glucose levels- 
Gluconeogenesis 
While most cell systems utilize circulating glucose for production of energy, liver, kidney 
and skeletal muscle cells generate glucose endogenously from non-carbohydrate sources 
such as pyruvate, lipids and amino acids, in a process termed as gluconeogenesis. Low 
blood glucose levels are an indicator for hepatic cells to increase their rate of 
gluconeogenesis (9). This is a highly energy consuming process, and cell systems in need 
of exogenous glucose are less likely to employ gluconeogenesis to produce glucose to be 
secreted out of the cell. Gluconeogenesis is a metabolic pathway that works in the reverse 
direction to glycolysis, and includes all the reversible reactions of glycolysis, utilizing the 
same enzymes (Fig. 2). It also involves 3 irreversible steps, utilizing specialized 
Fig. 2- A diagrammatic representation of the pentose phosphate pathway. P- Phosphate groups 
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gluconeogenic enzymes- glucose-6-phosphatase (G6Pase), fructose-1,6 bisphosphatase-1 
(FBP1) and phosphoenol pyruvate carboxykinase (PEPCK).  
Fructose-1,6-bisphosphatase is the rate limiting enzyme for gluconeogenesis, which 
catalyzes the irreversible conversion of fructose-1,6-bisphosphate (F1,6BP) to fructose-6-
phosphate (F6P). It localizes to the cytoplasm, where it actively participates in 
gluconeogenesis. FBP1 is a 37 kD protein which has a regulatory domain at its amino (N) 
terminus and a catalytic domain at its carboxy (C) terminus. AMP and cAMP bind to the 
Glyceraldehyde phosphate 
dehydrogenase 
Fig. 3- Glycolysis and gluconeogenesis, with the enzymes involved in brown and blue 
respectively. 
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N terminus to allosterically regulate the activity of the enzyme (10). FBP1 is found to be 
downregulated in renal carcinomas, breast cancers and hepatocellular carcinomas and is 
being increasingly recognized as a tumor suppressor. Loss of FBP1 increases glucose 
consumption and enhances metastasis (10-12). 
According to The Human Protein Atlas, FBP1 is expressed as a protein in tissues like 
liver, small intestine, thyroid gland, stomach and kidney. It has not been reported to be 
expressed in tissues originating from the bone marrow, specially lymphocytes. Presence 
of FBP1 mRNA was detected in an RNA sequencing study in lymphocytes (13), but its 
protein expression in the cell has not been studied before. 
Our lab is interested in metabolic alterations and reprogramming associated with the 
proliferating phenotype, and uses primary human T cells for modeling proliferative 
systems. Targeted metabolomics with non-radioactive heavy isotopomers of metabolites 
have been instrumental in tracing the fate of these metabolites after they are taken up by 
the cells. Labeling of glucose with [13C] carbons at different positions enables us to study 
its trajectory through glycolysis, TCA cycle, or the pentose phosphate pathway. We have 
utilized glucose labeled at positions 1 and 2 ([13C]-1,2-glucose) to study glycolysis and 
the TCA cycle. We also utilized glucose with a labeled carbon at position 6, to study the 
PPP, since the carbon at position 6 is retained during the reactions of the PPP when it 
Fig. 4- Fate of [
13
C]-6-glucose through the PPP. The labeled carbon is indicated with the red 
circle. S7P- Sedoheptulose-7-Phosphate, E4P- Erythrose-4-Phosphate, X5P- Xylose-5-Phosphate 
Glucose 
G6P 
F6P 
F1,6P 
G3P DHAP 
S7P 
E4P 
X5P 
6-Phsophogluconate Ribulose-5-Phosphate 
Ribose-5-
Phosphate 
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forms G3P to continue glycolysis (Fig. 4). An unexpected labeling pattern of glycolytic 
intermediates emerged from this approach and led us to formulate the hypothesis that is 
the basis of this dissertation project.  We hypothesize that FBP1, a gluconeogenic 
enzyme, is expressed and functional in T cells, but may play a novel ‘non-gluconeogenic’ 
role. We also observed a unique shorter isoform of FBP1 in activated T cells. The 
experiments, described in the following chapter, investigate and begin to characterize this 
unique FBP1 isoform.  
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Chapter 2: Results  
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1. Targeted metabolomics suggest catalytically active fructose bisphosphatase-1 
is expressed in activated T cells - 
We described in the previous chapter how isotope tracer experiments are useful for 
tracking the metabolism of nutrients like glucose and glutamine through the various 
metabolic pathways in a cell. Replacing glucose carbons at various positions with a 
heavier isotope, [13C], labels the carbon atom and can be detected by mass spectrometry 
as the glucose is taken up and metabolized. Each added [13C] increases the mass number 
of the molecule by 1 unit (m+1, m+2 and more). The position of the labeled carbon on 
the isotopomer is selected based on the focus of the experiment. Glucose with labeled 
carbon at position 1 and 2 ([13C]-1,2-glucose) or at all six positions (uniformly labeled) is 
used to study glycolysis and TCA cycle. We used singly labeled [13C]-6-glucose for our 
experiments, to study the trajectory of the glucose molecule through the PPP (Fig. 4). 
Human CD3+ T cells were isolated from peripheral blood mononuclear cells (PBMCs), 
and co-stimulated in vitro with anti-CD3 and anti-CD28 antibodies. These cells were 
cultured in [13C]-6-glucose following co-stimulation, harvested 24 hours later and cell 
extracts analyzed by mass spectrometry. An unexpected labeled metabolic intermediate 
was detected in activated T cells (Fig. 5A and 5B). Along with the predicted m+1 labeled 
F6P and F1,6BP, close to 20% of m+2 labeled F6P and F1,6BP were also detected in 
activated cells (Fig. 5C and 5D). Dihydroxy acetone phosphate (DHAP) and 
glyceraldehyde-3-phosphate (G3P) can each acquire the labeled carbon atom from 
glucose in the interconversion reaction. They can combine to form fructose-1,6-
biphosphate (F1,6BP) (m+1 or m+2) via the bidirectional reaction catalyzed by aldolase. 
Thus, the presence of m+2 F1,6BP was not surprising. The presence of doubly labeled 
F6P, however, was unexpected as the enzyme phosphofructokinase (PFK) that converts 
F6P to F1,6BP is unidirectional unlike most other glycolytic enzymes, with the reverse 
reaction F1,6BP back to F6P requiring a different unidirectional enzyme fructose 
bisphosphatase 1. 
The dual labeling of F6P can only be explained by FBP1 actively converting F1,6BP 
back to F6P. This unexpected labeling was the initial observation that led us to 
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hypothesize that FBP1 is expressed and enzymatically active in activated T cells. The 
presence of an active FBP1 suggested that gluconeogenesis, leading to production and 
secretion of glucose, may be occurring in T cells. We, therefore, looked for the 
expression of other two gluconeogenic enzymes, PEPCK and G6P in the T lymphocytes. 
 
2. FBP1 is the only gluconeogenic enzyme expressed in T cells 
Gluconeogenesis is a major metabolic pathway used by humans and other primates to 
maintain and restore blood glucose levels. It occurs primarily in the liver, and 
occasionally in the kidneys and small intestine. The results from the labeling experiments 
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Fig. 5- A) Expected labeling pattern in activated T cells with [
13
C]-6-glucose. B) Observed 
labeling in activated T cells with [
13
C]-6-glucose. C) and D) Enrichment of m+1 and m+2 F1,6BP 
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(Fig. 5) were surprising as T cells are not known to carry out gluconeogenesis. Moreover, 
the glucose-rich cell culture medium in which the T cells were activated in vitro made it 
unlikely that they would need to produce glucose. The targeted metabolomics suggested 
that at least one gluconeogenic enzyme, FBP1, was expressed in T cells, so we next 
checked for expression of the other two, PEPCK and G6Pase. We activated T cells for 24 
hours and analyzed RNA from unstimulated and stimulated cells for expression of FBP1, 
PEPCK and G6Pase mRNA by RT-PCR using the hepatocellular carcinoma cell line 
HepG2 as a positive control. We detected FBP1 mRNA, but no PEPCK or G6Pase 
expression, in the T cells using this approach (Fig. 6A and B). We conclude, based on 
these data, that T cells are not gluconeogenic and hypothesize that active FBP1 may have 
a unique, non-gluconeogenic role in activated T cells. 
 
3. Western blotting reveals two isoforms of FBP1 expressed in stimulated T 
cells. 
Analysis of T cell mRNA revealed the presence of FBP1 transcripts in both unstimulated 
and stimulated T cells. However, the labeling pattern of F6P indicative of an active 
FBP1, was observed only in stimulated T cells.  Next, lysates from CD3+ T cells 
activated for 24 hours in vitro with anti-CD3 and anti-CD28 antibodies, were analyzed 
for FBP1 protein expression by western blotting (Fig 7). Acute myeloid leukemia cell 
line, HL60, was used as a positive control for FBP1 expression (16). FBP1 was detected 
in unstimulated as well as CD3+ stimulated T cell lysates at 37 kD, the reported size of 
A 
Fig. 6- PCR amplification of gluconeogenic mRNA in T cells. A) amplification of FBP1 transcript 
in unstimulated (U) and stimulated (S) T cells. B) amplification of PEPCK, G6P and actin mRNA in 
T cells, using HepG2 cells as positive control. 
U S 
FBP1 
Actin 
U U S S HepG2 HepG2 
PEPCK G6P 
HepG2 U S 
ACTIN 
B 
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the full-length protein. The FBP1 antibody also detected a prominent 27 kD band only in 
stimulated T cells. A 27 kD band had previously been observed in western blots of mouse 
liver cell lysates and in HEK293 cells transfected with an FBP1 expression plasmid, but 
had not been described as an FBP1 isoform (18). To eliminate the possibility that the 27 
kD band was a result of non-specific binding of the FBP1 antibody, we tested four 
independent monoclonal and polyclonal antibodies from different sources. All four 
detected the shorter 27 kD band.  Representative data with two of these antibodies are 
shown in Fig. 7A and 7B. The data strongly suggest that the 27 kD protein is an isoform 
of FBP1 induced in activated T cells. 
 
4. Both isoforms of FBP1 are highly stable proteins in T cells 
To further confirm the identity of the putative shorter FBP1 isoform we attempted to 
knock down protein expression through RNA interference using siRNA. Human CD3+ T 
cells were activated 24 hours after transfection with FBP1 specific siRNA and analyzed 
for FBP1 protein and mRNA expression following 24 hours after activation. Despite 
strong silencing at the RNA level (Fig. 8A and 8B) western blots showed no decrease in 
the levels of either isoform of FBP1, in unstimulated or in stimulated T cells (Fig. 8C). 
However, FBP1 specific siRNA decreased mRNA as well as protein expression in control  
Fig. 7- Western blot of cell lysates from two independent human T cell donors showing the 
shorter isoform at 27kD detected by A) ThermoFisher anti-FBP1 antibody (PA5- 30028) and 
B) Santa Cruz anti-FBP1 antibody (sc-166145). U: Unstimulated S: Stimulated. HL60 cells 
were used as a positive control for FBP1 expression 
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HL60 cells (Fig. 8D and 8E). This suggested that both isoforms of FBP1 are highly stable 
in T cells. To test this possibility, we looked at expression of both isoforms of FBP1 in T 
cells exposed to the protein synthesis inhibitor cycloheximide. CD3+ unstimulated and 
stimulated T cells were incubated with cycloheximide and protein expression was 
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Fig. 8-  Fold change in FBP1 mRNA in A) unstimulated and B) stimulated T cells transfected 
with control and FBP1 siRNA measured by qPCR C) Western blot of cell lysates from 
unstimulated (U) and stimulated (S) T cells transfected with control (siCON) and FBP1 
(siFBP1) siRNA, harvested after 24 hours of activation. D) Fold change in FBP1 mRNA in 
HL60 cells transfected with control and FBP1 siRNA E) western blot of cell lysates of HL60 
cells transfected with FBP1 siRNA 
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determined at the indicated times by western blot (Fig. 9A and 9B). Levels of both 
isoforms of FBP1 were unaffected for as long as 30 hours in both unstimulated and 
stimulated T cells. The loss of expression of Noxa, a Bcl-2 protein consistently induced in 
activated T cells (14) shown in Fig 9C confirmed that the cycloheximide treatment had 
been effective. Based on these data we conclude that both isoforms of FBP1 are highly 
stable proteins in T cells. 
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Fig. 9- Western blot showing protein expression of FBP1 in A) unstimulated and B) stimulated T 
cells indicated hours after treatment with DMSO or 10µg/mL Cycloheximide (CHX) C) Protein 
expression of Bcl-2 protein Noxa in stimulated T cells after treatment with DMSO or 10µg/mL 
CHX indicating effectiveness of CHX treatment. 
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5. Mechanism of regulation of FBP1 expression in T cells. 
We have determined that T cells express a shorter isoform of FBP1, upon activation in 
vitro. A similar short isoform was observed previously in lysates of HEK293 cells 
transfected with a full-length FBP1 expression plasmid, and in western blots of mouse 
liver lysates (18). There are three possible regulatory mechanisms that could lead to the 
generation of the short isoform:  
1) Alternative splicing of FBP1 mRNA could result in a shorter transcript, however, RT–
PCR with different sets of primers showed full length transcripts of FBP1 to be present in 
both stimulated and unstimulated cells (data not shown), eliminating alternative splicing 
as a possible mechanism.  
A MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGST
NVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNID
CLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIG
EFILVDKDVKIKKKGKIYSLNEGYARDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTL
VYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGS
PDDVLEFLKVYEKHSAQ 
B 
Fig. 10 A) Sequence of FBP1 protein with the methionine at position 1, 83 and 85 indicated in 
bold.  B) Crytsal structure of FBP1 showing the regulatory domain (green) with bound AMP 
molecule and the catalytic domain (purple) bound F6P molecule.  
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2) Full length translated FBP1 protein could be subject to cleavage by proteolytic 
enzymes such as caspases, following activation. A scan of the amino acid sequence of 
FBP1 located a few caspase cleavage sites none of which, if utilized, was likely to yield a 
protein fragment of size 25-27kD. 
3) Utilization of an internal translation start site on the full-length transcript could result 
in translation of a shorter protein.  This appears to be the most likely mechanism. We 
hypothesize that the T cells are utilizing an alternative internal start site to translate the 
shorter isoform.  The amino acid sequence of FBP1 (Fig. 10A) contains two methionine 
residues at position 83 (M83) and 85 (M85), either of which can potentially serve as 
initiator methionines for translation.  The size of a protein translated starting at either of 
these residues is predicted to be 25-27 kD. The methionine residue at position 85 is 
conserved in mouse FBP1, where the shorter isoform was previously detected (18). 
An alternative internal start site for FBP1 could have the following regulatory effect. As 
described in the introductory chapter, FBP1 harbors a regulatory domain at the N 
terminus and a catalytic domain at the C-terminus (Fig. 10B). The N-terminal regulatory 
domain can interact with AMP which inhibits its activity.  We hypothesize that utilization 
of either M83 or M85 for initiation of translation by activated T cells would generate a 
constitutively active enzyme harboring only the catalytic domain.  
To begin to test the hypothesis that the shorter FBP1 is constitutively active, we 
subcloned full length FBP1, M83 and M85 cDNAs carrying a 3’ V5 tag into EcoRI and 
HindIII restriction sites of the pCDNA 3.1(-) mammalian expression plasmid (Fig. 11). 
M83 
FBP
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25-
27kD 
25-
27kD 
M1 
M83 
M85 
Fig. 11- Diagrammatic representation of truncated FBP1 isoforms translated from the FBP1 
expression plasmids, with M1, M83 and M85 as the starting methionine, and their expected 
protein sizes 
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Selected constructs were sequenced for accuracy, purified and used as templates for in 
vitro translation in the TnT Quick Coupled Transcription/Translation System (ProMega 
Biotech). In vitro translated full length wildtype FBP1 as well as the M83 and M85 forms 
were detected at the expected size after immunoprecipitation with anti-V5 tag antibody 
and subsequent western blotting with anti-FBP1 antibody (Fig. 12A and 12B). In vitro 
translated isoforms of FBP1 were also recognized by an antibody that could detect the 
shorter isoform in activated T cells. We also checked for intracellular expression by 
transfecting the plasmids into human embryonic kidney cell line HEK293 and subjecting 
cell extracts to immunoprecipitation with anti-V5 antibody. Along with the full length 
FBP1 band at 37kD, we observed an additional band at 27kD in HEK293s transfected 
with WT FBP1. The full-length construct expressed both forms in HEK293, confirming 
previous reports and validating in part that the shorter peptide is an FBP1 isoform. 
However, M83 FBP1 and M85 FBP1 were not being translated in HEK293 cells. 
Possible implications of this observation will be discussed in the next section. 
Fig. 12- A) and B) Immunoprecipitation of FBP1 constructs translated in vitro, with anti-V5 tag 
antibody, and subsequent western blotting with ThermoFisher anti FBP1 antibody C) and D) 
Immunoprecipitation of FBP1 constructs with anti-V5 tag antibody from lysates of HEK293 cells 
transfected with FBP1 constructs. No Transf- No transfection, pcDNA- HEK298 cells transfected 
with empty pcDNA 3.1(-) vector.  
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These results strengthen the hypothesis that the additional shorter band detected in T cells 
is indeed FBP1. The shorter isoform that appeared in HEK293s was after 
immunoprecipitation by an anti-V5 tag antibody, which suggests an intact C-terminus. 
This further supports the hypothesis that it is the N-terminus of the protein that is lost in 
the shorter isoform. Targeted metabolism had suggested the presence of a catalytically 
active FBP1 in stimulated T cells, which we hypothesize is likely to be a constitutively 
active shorter isoform. 
 
6. Both isoforms of FBP1 are in separate larger complexes-   
 
We have begun to characterize the two isoforms as we test our hypothesis that the shorter 
form is an enzymatically active protein, while the full-length lacks activity. To determine 
whether the two isoforms fractionate together or are components of independent protein 
complexes, cell extracts from unstimulated and stimulated T cells were fractionated on a 
Superose 6 gel filtration column, which separates cellular protein complexes by size. 
Western blots of fractionated extracts (Fig. 13A and 13B) show that the 37 kD isoform of 
FBP1 consistently eluted between fraction 15 and 17 (~200 kD), whereas the 27 kD 
B 
Fraction  Input 7 8 9 10 11 12 13 14 15 16 
37kD 
20 19 18 17 21 
FBP1 
Fraction 
37 
10 11 12 13 15 14  16 17 Input 19 18 
Fig. 13. Western blots of protein fractions collected from the Superose column. A) 37kD isoform of 
FBP1 fractionates in a high molecular weight complex in unstimulated T cells. B) Both isoforms on 
FBP1 in stimulated T cells elute in different high molecular weight complexes. Cells were lysed in 
Buffer A, and loaded on Superose 6 columns. 1mL fractions were collected every 10 mins, and purified 
protein was analyzed by SDS-PAGE 
A 
27 
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isoform emerged in fractions 17 to 20 (~80 kD) The ability to physically separate the two 
isoforms in their native forms will enable us to test them individually for catalytic 
activity.  The multiprotein complexes are likely to be physiologically relevant and may 
offer valuable insights into the regulation and catalytic activity of this interesting 
metabolic enzyme. 
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The activation process in T lymphocytes is accompanied by significant reprogramming of 
metabolic networks including a switch to aerobic glycolysis, to fuel increased 
biosynthetic demands of proliferation (3). Similar metabolic alterations occur in cells as 
they acquire tumorigenicity. The Kelekar lab is interested in T cell metabolism as a 
model for metabolic reprogramming in proliferating systems. Early studies with a 
specific singly-labeled glucose isotopomer led to the discovery that FBP1 was expressed 
in T cells.  In fact, FBP1was the only gluconeogenic enzyme expressed in T cells, leading 
us to hypothesize that it harbors a novel, non-gluconeogenic function.  
We also report, for the first time, the presence of a shorter isoform of FBP1 unique to 
activated T cells, that is induced within an hour of activation, and remains upregulated for 
96 hours, post stimulation. We hypothesize that the cells use an internal methionine 
residue either at position 83 or 85 as a start site for translation of the short peptide. The 
methionine at position 85 is conserved in mouse FBP1, where the shorter isoform was 
previously described (18). The codon for M85 also has a better Kozak consensus, 
favoring its probability as a start site. AMP and cAMP bind to the N-terminus of the 
protein, allosterically inhibiting its catalytic activity. Thus, a shorter protein devoid of the 
N-terminal regulatory domain would be predicted to be constitutively active.  
To further characterize this isoform and test our hypotheses, we generated plasmid 
constructs that would express the predicted shorter FBP1 proteins. These isoforms could 
be translated in an in vitro system, but were unable to produce detectable protein when 
transfected into HEK293 cells. However, both the shorter isoform and the full-length 
protein were detected, in HEK293 cells transfected with the WT FBP1 plasmid construct. 
It is possible that the shorter isoforms, being constitutively active, are not favored by the 
tumor cell line, in keeping with reports that have found FBP1 to be downregulated in 
cancer. Alternatively, an unknown regulatory protein may need to interact with the region 
of FBP1 transcript coding for the N terminus (missing in the deletion constructs) to 
facilitate intracellular translation from an internal methionine residue.  
We hypothesize that the short FBP1 isoform is constitutively active. However, its 
catalytic activity remains to be determined. The enzymatic activity of in vitro translated 
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products immunoprecipitated with the V5 antibody will be assayed in the following 
manner. Translated protein or cell lysates will be added to a reaction mixture containing 
the required substrates NADP+ and fructose-6-phosphate. A readout for the phosphatase 
activity will be obtained by coupling it with exogenous phosphoglucose isomerase and 
glucose-6-phosphate dehydrogenase and measured by following NADPH formation (15).  
Using this assay, we will also evaluate FBP1 activity in T lymphocyte extracts 
fractionated by size-exclusion chromatography (shown in Fig 13). This approach will 
allow us to test our hypothesis of a constitutively active isoform in activated T cells and 
the inhibitory effect of AMP on the enzymatic activity.  
In the metabolic framework of a cell, FBP1 occupies a crucial junction between 
glycolysis, the PPP and gluconeogenesis. The observed dual labeling suggests a molecule 
of glucose being diverted to the PPP more than once, for which catalytic activity of FBP1 
is necessary (Fig. 5B). The absence of other gluconeogenic enzymes indicates a non-
gluconeogenic role for FBP1 which may be related to the PPP in activated T cells.  We 
hypothesize that FBP1 facilitates an increased flux of glucose into the pentose phosphate 
pathway, to increase the production of NADPH in the cells.  Soon after activation, T cells 
experience a phase of high metabolic activity, which can lead to increased free radical 
generation in the cells. There is also an elevated demand for biosynthetic precursors like 
lipids, for synthesis of membranes (4). Increased NADPH may serve both these purposes, 
being utilized to decrease the ROS in the cells, or to increase the rate of lipid synthesis. 
Preliminary observations indicate an inverse correlation between levels of FBP1 isoform 
and ROS over time in activated T cells. The enzyme may also have a role in increasing 
nucleotide synthesis through the PPP and enhancing proliferation, which can be 
monitored at the time cells enter a phase of rapid cell division. An immediate and stable 
induction of FBP1 upon stimulation indicates a significant physiological role for FBP1 in 
the metabolic reprogramming in T cells. More investigations, such as the use of an FBP1 
specific inhibitor, would help to accurately describe the physiological role of FBP1 in T 
cells. Approaches to further investigate FBP1 expression in T cells include studying its 
expression under metabolic stress, analyzing the effect of glucose deprivation on FBP1 
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expression. It would also be important to investigate FBP1 expression in differentiated T 
cell populations and to study the effects of FBP1 inhibition on T cell differentiation in 
vitro as well as in vivo using mouse models.  
Experiments are also underway to determine the sequence identity of the shorter isoform 
via mass spectrometric analysis. Size exclusion based chromatography suggest that both 
isoforms of FBP1 are components of larger multiprotein complexes.  Identification of the 
components of these complexes could offer clues to their physiological role in T cell 
activation. FBP1 was also the only gluconeogenic enzyme expressed in the acute myeloid 
leukemia cell (AML) line HL60 (data not shown), which we have used as a positive 
control in our studies. FBP1 has been reported to be expressed in HL60 cells upon 
differentiation, but little is known about its physiological significance (16).  
Recent publications have shown an association of gastric, breast and renal cancers with 
decreased FBP1 expression (10-12, 17). Our observations in T cells suggest that FBP1 
plays a significant role in T cell activation and proliferation. It would also be interesting 
to study its expression in AML and other such malignancies. Expression of FBP1 in a 
non-gluconeogenic setting, such as a proliferative cell system, is yet to be explored.  The 
results obtained so far lay the foundation for a significant role for FBP1 in T lymphocyte 
activation, differentiation, and effector functions via T cell metabolism. Further 
investigations into novel functions of FBP1 could offer useful insights into T cell 
physiology, autoimmune disorders and cancer immunotherapy, and could eventually aid 
in the development of effective therapeutics.  
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Cell lines and cell culture- 
HL60, cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 100 
U/ml penicillin, 100 μg/ml streptomycin, NEAA and 4 mM L-glutamine. HepG2 and 
HEK293 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. Cells 
were maintained in a humidified atmosphere of 5% CO2 at 37°C. 
 
Primary T cell isolation and activation- 
Human PBMCs were obtained from healthy donors via Memorial Blood Centre, St. Paul, 
MN, USA and purified from red blood cells using Histopaque (Sigma Aldrich). CD3+ T 
cell were isolated from PBMC’s by negative separation using Pan T cell isolation kit 
(Miltenyi). Briefly, PBMCs were passed through MACS separation columns (Miltenyi), 
and allowed to recover in RPMI-1640 supplemented with 10% FBS, 100 U/ml penicillin, 
100 μg/ml streptomycin, NEAA and 4 mM L-glutamine overnight. At 18 hours, live T 
cells were recovered by Ficoll density gradient centrifugation and allowed to rest for 2 
hours in RPMI medium. Culture dishes were coated with 5µg/mL of anti-CD3 antibody 
(BioLegend, San Diego, CA, USA) and incubated for 2 hours at 37°C. T-cells were then 
transferred to the coated culture plates and 5µg /mL of anti-CD28 antibody was added to 
the culture medium. The cells were collected 24 hours after activation unless specified 
otherwise. 
 
Metabolomic labelling experiments-  
Live, healthy T cells were recovered by Ficoll density gradient centrifugation and 
activated as described earlier. At T0 10E6-20E6 cells per sample were pelleted and washed 
in glucose free medium. For glucose labeling experiments, cells were resuspended at 1E6 
cells/ml in glucose free medium supplemented with 10% dialyzed FBS, NEAA, and 
4mM L-glutamine for 1 hour. After starvation, cells were supplemented with 10mM [6-
13C] labeled glucose for 3 hours. Cells were then pelleted and washed 1X in ice cold PBS. 
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Pellets were then resuspended in 100-200μl -20°C methanol, snap frozen and stored at -
80C. Liquid chromatography/mass spectrometry (LC/MS) and gas chromatography/mass 
spectrometry (GC/MS) were used for identification and quantification of labeled 
metabolites of all samples. [6-13C] glucose was purchased from Cambridge Isotopes 
(Tewksbury, MA USA). 
 
FBP1 knockdown experiments- 
T cells were isolated from PBMCs as described before, and live cells were recovered by 
Ficoll density gradient 18 hours after isolation. The cells were rested for 2 hours after 
recovery, and transfected with 100mM of FBP1 specific and non-targeting siRNA 
respectively (Dharmacon), using the Neon Transfection system (Invitrogen). The cells 
were cultured overnight in RPMI 1640 medium supplemented with 10% FBS, NEAA and 
4mM L-glutamine. On the next day, plates were coated with anti CD3 antibodies for 2 
hours as described before, and 24 hours after transfection, the cells were activated as 
described earlier. Protein and mRNA were harvested from the cells 24 hours after 
activation. 
 
Plasmid Constructs- 
FBP1 pcDNA 3.1 V5-His-TOPO plasmid construct was a generous gift from from Dr. M. 
Celest Simon. WT FBP1 (full length), FBP1 M83 and FBP1 M85 were amplified from 
the source vector to carry a 5’ EcoRI and a 3’ HindIII restriction site along with a 3’ V5 
tag. The forward primers used for the PCR reaction were: 
FBP1 full length-  5’- CATGATGAATTCACCATGGCTGACCAGGCGCCCTTC- 3’,  
FBP1 M83- 5’- CATGATGAATTCACCATGAACATGTTAAAGTCA- 3’,  
FBP1 M85- 5’- CATGATGAATTCACCATGTTAAAGTCATCCTTT- 3’.  
The reverse primer used was 5’- CATGATAAGCTTTCACGTAGAATCGAGACC- 3’. 
The vector, pcDNA 3.1 (-) was dephosphorylated with alkaline phsophatases. The 
amplified PCR band was PCR purified by Qiagen PCR purification kit, digested with 
EcorI and HindIII, and cloned into pcDNA 3.1(-), digested with the same restriction 
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enzymes. The inserts were ligated with the digested plasmid in 1:4 (plasmid: insert) 
ration using T4 DNA ligase. The plasmid was then transformed into DH5α competent E. 
coli cells. After selection of transformed bacteria by Carbenicillin, E. Coli were cultured 
in large quantities, and the plasmid DNA was isolated using Qiagen Maxi Prep kit. The 
DNA insert cloned into pcDNA 3.1 was sequenced to confirm that there were no 
mutations.  
 
In-vitro translations of plasmid constructs- 
In vitro translations of plasmid constructs were carried out using the TnT Quick Coupled 
Transcription/Translation Systems (Promega). The components for a 20µL mix were: 
16µL TnT Quick Master mix, 0.5µL Methionine, 1 µL plasmid DNA (0.5µg/ µL), 2.5µL 
nuclease free water. The mixture was incubated at 30°C for 90 minutes and stored at -
20°C until further use.  
 
HEK293 Transfections- 
Transfections of 293s was done in 6- well plates. 3µL of Fugene reagent (Promega) and 
97µL of Opti-MEM medium (Promega) were incubated together for 5 minutes. To this 
mixture, 1µg of respective construct (WT, M83 and M85) was added and incubated for 
15 minutes. The cells were fed with DMEM medium with 10% serum, and the 
transfection mix was added to the wells. The cells were harvested 48 hours after 
transfection and lysed in Dignam Buffer A. 
 
Western Blots- 
Cells were washed with 1x cold PBS and lysed with RIPA buffer (50mM Tris-HCl [pH 
7.5]), 150mM NaCl, 0.5% v/v sodium deoxycholate, 1% v/v Nonidet P-40, 0.1% SDS 
supplemented with protease and phosphatase inhibitor cocktails. Lysates were incubated 
on ice for 10 minutes and spun at 10000 rpm for 10 minutes at 4°C. The supernatant was 
collected for further analysis. 30-40 µg of protein was boiled in 2x Laemlli buffer and 
resolved by SDS-PAGE, transferred to nitrocellulose membrane and probed with 
antibodies specific for FBP-1 (ThermoFisher-PA5-30028, Santa Cruz- 166145, Santa 
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Cruz- 376388) Chemiluminescence reactions were carried out using ECL plus kit 
(Amersham). 
 
Immunoprecipitation- 
HEK293 cells were lysed in Dignam Buffer A (10mM HEPES, 0.015mM MgCl2, 10mM 
KCl, 0.05% IGEPAL). Cell lysate equivalent to 200µg of protein was incubated with 
1.5µg of anti V5 tag antibody (ProteinTech 66007-1-Ig) at 4°C overnight. The antibody-
protein complex was captured on ProteinG-Agarose beads (Invitrogen). 
Immunoprecipitates were resolved by SDS-PAGE and detected by western blotting as 
described earlier. For immunoprecipitations with in-vitro translations, 6µL of translated 
mix was incubated with 1.5µg of anti V5 tag antibody overnight. The complex was 
captured and processed as described earlier. 
 
RNA isolation-  
RNA was isolated from HepG2 and T cells with TRIZOL reagents (Invitrogen) as per the 
manufacturer’s protocol. The isolated RNA was dissolved in RNase free water. RNA 
concentrations were determined using the Thermo Scientific Nano Drop 2000 
Spectrophotometer. Samples were stored at -80°C until further use. 
 
Reverse Transcription- 
cDNA synthesis was performed with 500-800ng RNA using the DyNAamo Synthesis Kit 
for qRT-PCR (Thermo Scientific) per the manufacturer’s protocol using random hexamer 
primers. The reaction program is: primer extension at 25°C for 10 min, cDNA synthesis 
at 37°C for 1 hour and reaction termination at 85°C for 5 min. cDNA products were 
stored at -20°C until further use. 
 
PCR to measure gluconeogenic enzyme mRNA levels in T cell, HepG2 cell mRNA- 
The oligonucleotide sequences for each primer are as follows- 
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Primer Sequence 
FBP1 full length FWD 5’-ACAGCAGTCAAAGCCATCTC-3’ 
FBP1 full length REV 5’-GGTTCCACTATGATGGCGTG-3’ 
G6P FWD 5’-GAGACTGGCTCAACCTCGTC-3’ 
G6P REV 5’-CCTGGTCCAGTCTCACAGGT-3’ 
PEPCK FWD 5’-AAGAGACACAGTGCCCATCC-3’ 
PEPCK REV 5’-ACGTAGGGTGAATCCGTCAG -3’ 
 
Thermocycler PCR conditions were as follows: 1) 94°C for 2 min 2) 94°C for 30 sec 3) 
annealing temperature for 30 sec 4) 72°C for 1 min 5) Repeat steps 2-4 for 35 cycles 6) 
72 °C for 4 min. The annealing temperature for FBP1 primers was 57°C, for G6P and 
Actin primers was 59°C, and for PEPCK primers was 62°C. PCR products were run on a 
1.5% agarose gel, and bands were visualized under UV light. 
 
Fractionation of proteins/FPLC- 
The Superose 6 column was pre-equilibrated with Dignam Buffer A. T cells were isolated 
and activated as described previously, and collected after 24 hours of activation and 
washed with 1X cold PBS. Cells were then lysed in Dignam Buffer A and subsequently 
fractionated on a GE/Amersham Superose 6 FPLC column. For each fractionation, 1 mL 
fractions were collected every 10 minutes and samples were analyzed by SDS-PAGE and 
western blot after TCA precipitation. 
 
TCA precipitation- 
Protein was precipitated from fractionation samples by adding 250µL of trichloroacetic 
acid (TCA) to 1mL of sample, incubated at 4°C for 10 mins, and spun at 140000 rpm for 
5 mins at 4°C. The protein pellet was washed with cold acetone and heated at 95°C for 
10-15 minutes to drive off the acetone. The samples were then prepared for western blot 
as described before. 
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FBP1 half-life- 
CD3+ T cells were isolated from human PBMCs and cultured overnight as described 
before. After recovery of live cells by Ficoll gradient, the cells were activated with anti-
CD3 and anti-CD28 antibodies. Unstimulated and stimulated T cells were then treated 
with DMSO (control) or 10µg/mL Cycloheximide (Sigma). The cells were harvested at 
each time point after treatment, lysed in RIPA buffer and analyzed for protein expression 
by western blotting as described before.  
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